Une accélération du portefeuille produits - ACHAT - TP 12,1€
Nous initions ce matin la couverture de la société Crossject avec un objectif de cours de 12,1€ et une recommandation à ACHAT. La société qui se focalise sur des « Super génériques », c’est-à -dire la combinaison d’un produit générique avec son dispositif d’injection sans aiguille Zeneo, anticipe le lancement de son premier produit MTX/Zeneo dans l’Arthrite Rhumatoïde sur le marché en 2017. Avec 7 actifs en voie de développement, la société pourrait potentiellement réaliser un lancement tous les 6 mois à partir de mi 2017. Bien que notre approche soit extrêmement conservatrice (3 actifs valorisés dans notre modèle à ce stade), nous ressortons avec un potentiel de hausse de +43% versus le dernier cours côté.Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.